As a proof of principle for CrossDome, we used the tumor-associated peptide from MAGEA3 (EVDPIGHLY) as a query, and evaluated the capacity of our method to recover the known cross-reactive peptide derived from TITIN (ESDPIVAQY) among the top-ranked putative off-targets. The gene discussed is MAGEA3; the disease is neoplasm.